Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
Keywords :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
location
Contact Email
Phone number
Website URL
Similar Companies1000
AltruBio
AltruBio is a biopharmaceutical company developing targeted antibody therapeutics for cancer and immune-related inflammatory diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
Palatin Technologies
Palatin is a biopharmaceutical company developing medicines that target the melanocortin peptide receptor system.
Sector
Subsector
Location
total rounds
total raised
Arvinas
Arvinas is a pharmaceutical company that develops novel therapeutics to treat a variety of diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
Pandion Therapeutics
Pandion Therapeutics develops novel therapeutics for autoimmune diseases.
Sector
Subsector
Keywords
Location
total rounds
total raised
M&A Details1
Transaction name
Acquired by
Bristol Myers Squibb
announced date
Financials
Funding Rounds2
Number of Funding Rounds
Money Raised
Their latest funding was raised on 02.12.2019. Their latest investor Atlas Venture. Their latest round Venture - Series Unknown
Omega Funds
Omega Funds is a global life sciences-based investment firm that specializes in direct secondary transactions.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Atlas Venture
Atlas Venture invests in biotech startups with seed and early stage venture investments.
Sector
Subsector
Keywords
Location
total rounds
count Of Investments
count Of Exists
Abingworth
Abingworth collaborates with entrepreneurs to develop impactful health products in life sciences.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Novartis
Novartis is a Swiss healthcare company improving global patient lives.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
count Of Exists
Co-Investors
Investors4
Number of lead investors
Number of investors
Atlas Venture
Atlas Venture invests in biotech startups with seed and early stage venture investments.
Sector
Subsector
Keywords
Location
total rounds
count Of Investments
count Of Exists
Jean-Francois Formela
Jean-François Formela is a partner and focuses on new advances in biology and drug discovery technologies as well as novel therapeutics. He serves on the boards of Ataxion, Egalet (NASDAQ: EGLT), F-star, Intellia Therapeutics, Navitor, RaNA Therapeutics which he co-founded, Spero Therapeutics and ZappRx. Jean-François has been involved in the formation of companies such as Adnexus (acquired by BMS), ArQule (NASDAQ: ARQL), Annovation Biopharma (acquired by The Medicines Company), Arteaus Therapeutics (acquired by Lilly), Cellzome (acquired by GSK), deCODE (NASDAQ: DCGN, acquired by Amgen), Exelixis (NASDAQ: EXEL), MorphoSys (Xetra: MOR.DE), NxStage (NASDAQ: NXTM) and SGX Pharmaceuticals (NASDAQ: SGXP, acquired by Lilly). He was also an investor in Achillion (NASDAQ: ACHN), CoStim Pharmaceuticals (acquired by Novartis) and Horizon Pharma (NASDAQ: HZNP) as well as a board member of Biochem Pharma (NASDAQ: BCHE, acquired by Shire) and Novexel (acquired by AstraZeneca). Jean-François joined Atlas Venture in 1993 to build the U.S. life sciences franchise. Prior to joining Atlas, Jean-François worked at Schering-Plough, where he directed U.S. Phase IV studies in all therapeutic areas. Before that, he was responsible for the marketing of Intron A, Schering-Plough’s alpha-interferon. Jean-François began his career as a medical doctor and practiced emergency medicine at Necker University Hospital in Paris. Jean-François is a member of the Massachusetts General Hospital Research Advisory Council and a former trustee of the Boston Institute of Contemporary Art. He received his MD from Paris University School of Medicine, and his MBA from Columbia University.
current job
organization founded
Abingworth
Abingworth collaborates with entrepreneurs to develop impactful health products in life sciences.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Novartis
Novartis is a Swiss healthcare company improving global patient lives.
Sector
Subsector
Keywords
Location
total rounds
total raised
count Of Investments
count Of Exists
People
Founders5
Matthias Geyer
Matthias Geyer joined the Institute of Innate Immunity at the University of Bonn in 2014, establishing the research department in structural immunology. His research focuses on the activation and formation of the inflammasome, the regulation of eukaryotic transcription, and the interaction with the actin cytoskeleton. His laboratory employs biochemical methods to determine protein–protein interactions as well as the interaction to lipids, nucleic acids and small molecular ligands and X-ray crystallography, NMR spectroscopy, and electron microscopy for the structural analysis of protein-ligand complexes. Matthias spent 12 years as an independent research group leader within the Max Planck Society, working at the Max Planck Institute of Molecular Physiology and the Research Center caesar. Matthias studied Physics in Kiel, Bonn and Heidelberg and graduated in Biophysics at the Max Planck Institute for Medical Research in Heidelberg working in structural biology. He obtained the habilitation in biochemistry from the Medical Faculty at Heidelberg University.
current job
organization founded
Matthias Geyer
Luigi Franchi
Luigi Franchi is an Assistant Professor of Pediatric Hematology/Oncology at the University of Michigan and Director of the Immunology Oncology program. Prior to that he worked at Lycera, where he led target discovery, target validation, screening platforms development, preclinical drug discovery, biomarker discovery and translational medicine. Luigi’s work for the last 20 years has focused on the innate immune system. Based on his collection of highly cited papers, in 2015 Thompson Reuters selected him as one of World’s Most Influential Scientific Minds in the field of Immunology (top 100 scientist worldwide). Luigi earned a Medical Degree in Medicine and Surgery with honors from University of Rome La Sapienza and a Ph.D. in immunology from University of Rome Tor Vergata, and was a Research Fellow and Research Investigator at the University of Michigan.
current job
organization founded
Luigi Franchi
Anthony Opipari
Anthony W. Opipari is the Founder of Lycera.
current job
organization founded
Anthony Opipari
Gary Glick
Gary D. Glick is the Founder and Executive Chair at IFM Therapeutics.
current job
Gary Glick
